MCID: CYT005
MIFTS: 49

Cytomegalovirus Retinitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Cytomegalovirus Retinitis

MalaCards integrated aliases for Cytomegalovirus Retinitis:

Name: Cytomegalovirus Retinitis 12 52 43 15 17 71
Cmv Retinitis 12 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:0080160
MeSH 43 D017726
UMLS 71 C0206178

Summaries for Cytomegalovirus Retinitis

Disease Ontology : 12 A retinitis that has material basis in Cytomegalovirus.

MalaCards based summary : Cytomegalovirus Retinitis, also known as cmv retinitis, is related to neuroretinitis and cytomegalovirus infection. An important gene associated with Cytomegalovirus Retinitis is IL10RA (Interleukin 10 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Valganciclovir and Ganciclovir have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and retina, and related phenotypes are cellular and hematopoietic system

Wikipedia : 74 Cytomegalovirus retinitis, also known as CMV retinitis, is an inflammation of the retina of the eye that... more...

Related Diseases for Cytomegalovirus Retinitis

Diseases related to Cytomegalovirus Retinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 603)
# Related Disease Score Top Affiliating Genes
1 neuroretinitis 32.1 IFNG CD4
2 cytomegalovirus infection 31.0 TNF HLA-B HLA-A
3 pars planitis 30.9 HLA-DRB1 HLA-B HLA-A
4 uveitis 30.7 TNF IL10 IFNG HLA-B HLA-A CCR5
5 iridocyclitis 30.6 TNF HLA-B CD4
6 iritis 30.5 TNF HLA-B CD4
7 neuritis 30.5 TNF IL10 IFNG CCR5
8 optic neuritis 30.3 TNF IL10 HLA-DRB1 CCR5
9 hemophagocytic lymphohistiocytosis 30.2 TNF IL10 IFNG
10 acute graft versus host disease 30.1 TNF IL10 IFNG
11 chronic graft versus host disease 30.1 IL10 IFNG CD4
12 proteasome-associated autoinflammatory syndrome 1 30.0 TNF IL10 IFNG
13 toxoplasmosis 30.0 TNF IL10 IFNG HLA-DQB1 CCR5
14 lupus erythematosus 29.9 TNF IL10 IFNG HLA-DRB1 HLA-DQB1
15 nocardiosis 29.9 TNF CD4
16 candidiasis 29.8 TNF IL10 IFNG CSF2
17 dermatitis 29.8 TNF IL10 IFNG CSF2
18 colitis 29.8 TNF IL10RA IL10 IFNG HLA-DRB1
19 tuberculoid leprosy 29.7 IL10 IFNG CD4
20 acquired immunodeficiency syndrome 29.7 TNF IL10 IFNG HLA-B CSF2 CD9
21 common variable immunodeficiency 29.7 TNF IL10 IFNG HLA-B HLA-A
22 good syndrome 29.7 TNF CD8A CD4
23 ulcerative colitis 29.6 TNF IL10RA IL10 IFNG HLA-DRB1
24 combined t cell and b cell immunodeficiency 29.6 IL10 CD8A CD4
25 thrombocytopenia 29.5 TNF IL10 IFNG CXCL12 CSF2
26 pemphigus 29.5 TNF IL10 HLA-DRB1 HLA-DQB1
27 choroiditis 29.5 TNF IL10 IFNG CD4
28 hypopyon 29.5 HLA-B CD4
29 myasthenia gravis 29.4 TNF IL10 IFNG HLA-DQB1 HLA-B
30 myocarditis 29.4 TNF IL10 IFNG HLA-DQB1 HLA-B
31 severe combined immunodeficiency 29.4 IL10 IFNG CXCL12 CSF2 CD4
32 acute retinal necrosis syndrome 29.4 CD8A CD4
33 rheumatic disease 29.3 TNF IL10 IFNG HLA-DRB1 HLA-B
34 pulmonary tuberculosis 29.3 TNF IL10 IFNG HLA-DRB1 HLA-DQB1
35 chorioretinitis 29.2 TNF IL10 IFNG CD8A CD4
36 stomatitis 29.1 TNF IL10 IFNG CSF2 CD4
37 graft-versus-host disease 29.1 TNF IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-B
38 chickenpox 29.0 TNF IL10 IFNG CD8A CD4
39 immune deficiency disease 29.0 TNF IL10 IFNG HLA-B HLA-A CXCL12
40 pancytopenia 28.9 IFNG CSF2 CD8A CD4
41 vascular disease 28.9 TNF IL10 IFNG CXCL12 CD4
42 pneumonia 28.9 TNF IL10 IFNG CSF2 CD8A
43 t-cell leukemia 28.9 TNF HLA-B HLA-A CSF2 CD4
44 human immunodeficiency virus type 1 28.9 TNF IL10 IFNG HLA-B HLA-A CXCL12
45 keratitis, hereditary 28.8 TNF IL10 CD8A CD4
46 crohn's disease 28.7 TNF IL10RA IL10 IFNG HLA-DRB1 CD4
47 eye disease 28.7 TNF IL10 IFNG CSF2 CD8A CD4
48 acute t cell leukemia 28.7 CXCL12 CD8A CD4
49 pneumocystosis 28.5 TNF CD8A CD4 CCR5 CARTPT
50 bacterial infectious disease 28.4 TNF IL10 IFNG CSF2 CD8A CD4

Graphical network of the top 20 diseases related to Cytomegalovirus Retinitis:



Diseases related to Cytomegalovirus Retinitis

Symptoms & Phenotypes for Cytomegalovirus Retinitis

MGI Mouse Phenotypes related to Cytomegalovirus Retinitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 CCR2 CCR5 CD4 CD8A CD9 CSF2
2 hematopoietic system MP:0005397 10.18 CARTPT CCR2 CCR5 CD4 CD8A CD9
3 immune system MP:0005387 10.13 CARTPT CCR2 CCR5 CD4 CD8A CD9
4 endocrine/exocrine gland MP:0005379 10.06 CARTPT CD4 CD8A CD9 CSF2 HLA-DQB1
5 digestive/alimentary MP:0005381 10.03 CCR2 CCR5 CD4 HLA-DQB1 IFNG IL10
6 liver/biliary system MP:0005370 9.8 CCR2 CCR5 CXCL12 HLA-DQB1 IFNG IL10
7 neoplasm MP:0002006 9.7 CCR2 CCR5 CD9 CSF2 IFNG IL10
8 nervous system MP:0003631 9.7 CCR2 CCR5 CD4 CD8A CD9 CSF2
9 respiratory system MP:0005388 9.17 CCR2 CD9 CSF2 HLA-DQB1 IFNG IL10

Drugs & Therapeutics for Cytomegalovirus Retinitis

Drugs for Cytomegalovirus Retinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Pancrelipase Approved, Investigational Phase 4 53608-75-6
5 Anti-Infective Agents Phase 4
6 Antiviral Agents Phase 4
7 Ganciclovir triphosphate Phase 4
8 Gastrointestinal Agents Phase 4
9 pancreatin Phase 4
10
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
11
Acyclovir Approved Phase 3 59277-89-3 2022
12 Antibodies, Monoclonal Phase 2, Phase 3
13 Immunoglobulins Phase 2, Phase 3
14 Antibodies Phase 2, Phase 3
15 Immunologic Factors Phase 3
16 Antineoplastic Agents, Immunological Phase 2, Phase 3
17
Nelfinavir Approved Phase 2 159989-64-7 64143
18
protease inhibitors Phase 2
19 HIV Protease Inhibitors Phase 2
20 Anti-HIV Agents Phase 2
21
Aldesleukin Approved Phase 1 110942-02-4, 85898-30-2
22 Analgesics Phase 1
23 Interleukin-2 Phase 1
24 Analgesics, Non-Narcotic Phase 1
25
Zidovudine Approved 30516-87-1 35370
26
Tranexamic Acid Approved 1197-18-8 5526
27
Cefepime Approved, Investigational 88040-23-7 5479537
28
Piperacillin Approved 66258-76-2 43672
29
Ciprofloxacin Approved, Investigational 85721-33-1 2764
30
Warfarin Approved 81-81-2 6691 54678486
31
Methylprednisolone Approved, Vet_approved 83-43-2 6741
32
Fosfomycin Approved 23155-02-4 446987
33
Amikacin Approved, Investigational, Vet_approved 37517-28-5 37768
34
Haloperidol Approved 52-86-8 3559
35
Labetalol Approved 36894-69-6 3869
36
Tobramycin Approved, Investigational 32986-56-4 5496 36294
37
Methylprednisolone hemisuccinate Approved 2921-57-5
38
Zolpidem Approved 82626-48-0 5732
39
Prednisolone phosphate Approved, Vet_approved 302-25-0
40
Tazobactam Approved 89786-04-9 123630
41
Nifedipine Approved 21829-25-4 4485
42
Spironolactone Approved 1952-01-7, 52-01-7 5833
43
Prednisolone Approved, Vet_approved 50-24-8 5755
44
Molindone Approved 7416-34-4 23897
45 Prednisolone acetate Approved, Vet_approved 52-21-1
46
Rocuronium Approved 119302-91-9, 143558-00-3 441290
47
Sevelamer Approved 52757-95-6
48
Alfentanil Approved, Illicit 71195-58-9 51263
49
Ziprasidone Approved 146939-27-7 60854
50
Bosentan Approved, Investigational 147536-97-8 104865

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
2 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
3 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
4 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
5 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
6 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
7 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
8 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
9 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
10 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
11 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
12 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
13 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
14 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
15 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
16 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
17 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
18 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
19 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
20 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
21 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
22 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
23 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
24 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
25 A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00001061 Phase 2 Sevirumab;Foscarnet sodium;Ganciclovir
26 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
27 A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure Completed NCT00000691 Phase 2 Foscarnet sodium
28 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Completed NCT00004794 Phase 2 cidofovir
29 A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression Completed NCT00001034 Phase 2 Ganciclovir
30 A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression Withdrawn NCT00000697 Phase 2 Foscarnet sodium
31 A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00002321 Phase 1 Aldesleukin
32 A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis Completed NCT00002016 Phase 1 Sevirumab
33 A Phase I Study of a Fixed-Schedule Regimen of Alternating Oral and Intravenous Ganciclovir for Treatment of Cytomegalovirus Retinitis Completed NCT00001062 Phase 1 Ganciclovir
34 A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy Completed NCT00000673 Phase 1 Ganciclovir
35 A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir Completed NCT00000668 Phase 1 Ganciclovir
36 A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy Completed NCT00000970 Phase 1 Foscarnet sodium;Ganciclovir
37 Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome Completed NCT00000726 Phase 1 Foscarnet sodium
38 A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease Completed NCT00000805 Phase 1 Ganciclovir
39 A Phase I/II Study of Cidofovir for HIV-Infected Children With Invasive CMV (Cytomegalovirus) Disease Withdrawn NCT00000881 Phase 1 Cidofovir;Probenecid
40 Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures Unknown status NCT00002301 Foscarnet sodium
41 Vistide (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients With AIDS Unknown status NCT00002384 Cidofovir
42 An Open Study of Foscarnet Treatment of CMV-Retinitis in AIDS Patients Completed NCT00002432 Foscarnet sodium
43 A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis Completed NCT00002187 Fomivirsen sodium
44 An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS Completed NCT00002222 Valganciclovir
45 An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access Completed NCT00002135 Ganciclovir
46 An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients Completed NCT00002039 Foscarnet sodium
47 A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS Completed NCT00002034 Zidovudine;Ganciclovir
48 A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS Completed NCT00002257 Ganciclovir
49 A Randomized Comparison of Immediate Versus Delayed Treatment With Intravitreal Injections of ISIS 2922 in Patients With Peripheral Cytomegalovirus (CMV) Retinitis Completed NCT00002355 Fomivirsen sodium
50 A Randomized Study Comparing the Safety and Efficacy of Three Doses of Oral Ganciclovir to Intravenous Ganciclovir for the Maintenance Treatment of Cytomegalovirus Retinitis in People With AIDS Completed NCT00002330 Ganciclovir

Search NIH Clinical Center for Cytomegalovirus Retinitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cidofovir
fomivirsen
fomivirsen sodium
Ganciclovir
Ganciclovir Sodium
valganciclovir
Valganciclovir hydrochloride

Cochrane evidence based reviews: cytomegalovirus retinitis

Genetic Tests for Cytomegalovirus Retinitis

Anatomical Context for Cytomegalovirus Retinitis

MalaCards organs/tissues related to Cytomegalovirus Retinitis:

40
Eye, T Cells, Retina, Bone, Kidney, Lung, Bone Marrow

Publications for Cytomegalovirus Retinitis

Articles related to Cytomegalovirus Retinitis:

(show top 50) (show all 2070)
# Title Authors PMID Year
1
Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group. 54 61
7658051 1995
2
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. 54 61
1323624 1992
3
Parthanatos-associated proteins are stimulated intraocularly during development of experimental murine cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression. 61
31670405 2020
4
Cytomegalovirus disease in a retinoblastoma cohort: The role of preemptive screening. 61
31793213 2020
5
Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. 61
32016664 2020
6
Successful treatment of an AIDS patient with prolonged Mycobacterium avium bacteremia, high HIV RNA, HBV infection, Kaposi's sarcoma and cytomegalovirus retinitis. 61
31543435 2020
7
Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina. 61
31988033 2020
8
Spectrum of Newly Diagnosed Cytomegalovirus Retinitis in a Developing Country in the HAART Era. 61
30395753 2020
9
Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. 61
31992849 2020
10
Tofacitinib-associated cytomegalovirus retinitis. 61
31990341 2020
11
Cytomegalovirus retinitis after treatment with topical difluprednate in an aphakic eye of an immunocompetent patient. 61
31650081 2019
12
Cytomegalovirus Retinitis in HIV and Non-HIV Individuals. 61
31905656 2019
13
Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study. 61
31723570 2019
14
Cytomegalovirus Retinitis Diagnosis and Treatment in a Kidney Transplant Recipient. 61
31713491 2019
15
Letermovir for the Management of Cytomegalovirus-associated Uveitis. 61
31638841 2019
16
Prognostic Factors of Cytomegalovirus Infection Associated Retinitis in HIV-Negative Patients: A Retrospective Cohort Study. 61
31580185 2019
17
Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches. 61
31621449 2019
18
[The consistency of ultra-wide-field retinal imaging and the Superfield lens for fundus screening in HIV/AIDS patients]. 61
31607065 2019
19
Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. 61
30972869 2019
20
Abnormal levels of aqueous humor trace elements in patients with cytomegalovirus retinitis. 61
31065104 2019
21
Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. 61
31640581 2019
22
[Cytomegalovirus retinitis after an intravitreal dexamethasone implant]. 61
31543097 2019
23
CYTOMEGALOVIRUS RETINITIS WITH BELATACEPT IMMUNOSUPPRESSION. 61
31568220 2019
24
Infectious uveitis in immunodeficient HIV-negative patients: A retrospective study. 61
31435074 2019
25
A lymphoma patient with Cytomegalovirus retinitis and post-autologous hematopoietic cell transplantation immune reconstitution uveitis: A case report and review of the literature. 61
31033155 2019
26
Visual prognosis, clinical features, and predisposing factors in non-HIV patients with cytomegalovirus retinitis. 61
30030661 2019
27
Utility of ultra-widefield retinal imaging in the follow-up and management of patients with Cytomegalovirus retinitis. 61
31268742 2019
28
Routine Immediate Eye Examination at the Point of Care for Diagnosis of AIDS-Related Cytomegalovirus Retinitis Among Patients With a CD4 Count <100 in Myanmar. 61
31304189 2019
29
CYTOMEGALOVIRUS RETINITIS AFTER AN INTRAVITREAL DEXAMETHASONE IMPLANT IN AN IMMUNOCOMPETENT PATIENT. 61
31339873 2019
30
Autophagy protects against retinal cell death in mouse model of cytomegalovirus retinitis. 61
31291924 2019
31
Declining cytomegalovirus retinitis in ART- experienced women from North India. 61
31388246 2019
32
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. 61
31292125 2019
33
A comparative study on retinal thickness of the macular region among AIDS patients with normal ocular fundus, HIV-related microvascular retinopathy patients, and cytomegalovirus retinitis patients. 61
31261518 2019
34
[Diagnostic vitrectomy in intraocular inflammations: A retrospective series]. 61
31084938 2019
35
Presenting Features, Treatment and Clinical Outcomes of Cytomegalovirus Retinitis: Non-HIV Patients Vs HIV Patients. 61
31166809 2019
36
Ultra-Widefield Fundus Autofluorescence in Cytomegalovirus Retinitis. 61
31136217 2019
37
Aqueous cytomegalovirus DNA and interleukin-8 determination in management of cytomegalovirus retinitis. 61
30187638 2019
38
Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS. 61
31042791 2019
39
Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A review. 61
30859706 2019
40
Polymerase chain reaction analysis of aqueous humor specimens in the diagnosis of cytomegalovirus retinitis in AIDS patients. 61
30968705 2019
41
[The ocular manifestations of human immunodeficiency virus and syphilis coinfection]. 61
30982288 2019
42
Bilateral cytomegalovirus retinitis comorbid with diabetic macular edema. 61
31198672 2019
43
Cytomegalovirus Retinitis during Maintenance Therapy in child with Acute Lymphoblastic Leukemia. 61
31086168 2019
44
[Clinical characteristics and T-lymphocyte subsets in 48 acquired immune deficiency syndrome patients with cytomegalovirus infections]. 61
30803177 2019
45
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. 61
30642941 2019
46
A cross-sectional study of cytomegalovirus retinitis in HIV-1 infected adults in Nigeria. 61
30837414 2019
47
Concurrent cerebral toxoplasmosis and cytomegalovirus retinitis in a patient with human immunodeficiency virus. 61
30851795 2019
48
Uveitis causes according to immune status of patients. 61
30239127 2019
49
CD4+ cells as a potential biomarker for cytomegalovirus retinitis in children with acute lymphocytic leukemia. 61
30681505 2019
50
Active cytomegalovirus retinitis after the start of antiretroviral therapy. 61
30196272 2019

Variations for Cytomegalovirus Retinitis

Expression for Cytomegalovirus Retinitis

Search GEO for disease gene expression data for Cytomegalovirus Retinitis.

Pathways for Cytomegalovirus Retinitis

Pathways related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF IL10RA IL10 IFNG HLA-DRB1 HLA-DQB1
2
Show member pathways
13.68 TNF IL10RA IL10 IFNG CXCL12 CSF2
3
Show member pathways
13.41 TNF IL10RA IL10 CXCL12 CSF2 CD4
4
Show member pathways
13.3 TNF IL10RA IL10 CXCL12 CSF2 CD4
5
Show member pathways
13.21 TNF IL10RA IL10 IFNG HLA-DRB1 HLA-DQB1
6
Show member pathways
12.96 TNF IL10RA HLA-B HLA-A CXCL12 CSF2
7
Show member pathways
12.83 TNF IFNG HLA-DRB1 HLA-DQB1 HLA-B HLA-A
8 12.81 TNF IFNG HLA-DRB1 HLA-DQB1 HLA-B HLA-A
9
Show member pathways
12.68 TNF IL10RA IL10 IFNG HLA-DRB1 HLA-DQB1
10
Show member pathways
12.63 TNF IL10 IFNG HLA-DRB1 HLA-DQB1 CD4
11
Show member pathways
12.63 TNF IL10 IFNG CSF2 CD8A CD4
12
Show member pathways
12.61 TNF IL10RA IL10 IFNG CD4
13 12.59 TNF IL10 IFNG CXCL12 CD8A CCR2
14
Show member pathways
12.56 IFNG HLA-DRB1 HLA-DQB1 HLA-B HLA-A
15
Show member pathways
12.53 TNF IFNG HLA-B HLA-A CSF2
16
Show member pathways
12.4 TNF IL10RA IL10 CXCL12 CCR5 CCR2
17
Show member pathways
12.4 TNF IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-B
18
Show member pathways
12.36 IL10RA IL10 IFNG CSF2
19 12.34 TNF HLA-DRB1 HLA-DQB1 HLA-B HLA-A CSF2
20
Show member pathways
12.29 TNF IL10 IFNG HLA-B HLA-A CXCL12
21 12.27 TNF IL10RA IL10 IFNG HLA-DRB1 HLA-DQB1
22
Show member pathways
12.22 TNF IL10RA IL10 IFNG HLA-DRB1 HLA-DQB1
23 12.17 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
24 12.15 HLA-DRB1 HLA-DQB1 HLA-B HLA-A CD8A CD4
25
Show member pathways
12.08 TNF IL10 IFNG CD4
26 12.04 TNF IL10 IFNG CSF2 CD8A CD4
27
Show member pathways
12.01 IFNG HLA-DRB1 HLA-A CD8A CD4 CCR5
28
Show member pathways
11.99 HLA-DRB1 HLA-A CD8A CD4
29 11.95 TNF IL10 IFNG CSF2
30 11.95 IL10RA IL10 IFNG CXCL12 CCR5 CCR2
31 11.88 TNF IFNG HLA-DRB1 HLA-DQB1 CXCL12 CSF2
32 11.87 IL10 HLA-DRB1 HLA-DQB1
33 11.86 TNF IL10 IFNG CD8A CD4
34
Show member pathways
11.81 HLA-DRB1 HLA-DQB1 CD4
35 11.78 TNF IL10 IFNG CSF2
36 11.77 HLA-DRB1 CXCL12 CD4
37 11.77 HLA-DRB1 HLA-DQB1 CD8A CD4
38
Show member pathways
11.76 TNF IFNG CSF2
39 11.71 TNF IL10 IFNG CSF2 CD8A CD4
40
Show member pathways
11.7 TNF IFNG HLA-A CD8A
41 11.7 TNF HLA-DRB1 HLA-DQB1 CSF2 CD9 CD8A
42
Show member pathways
11.68 TNF IFNG CSF2
43 11.68 TNF CSF2 CCR2
44 11.57 TNF IL10 IFNG
45 11.55 TNF IFNG CCR2
46 11.53 IL10 IFNG CD4
47 11.42 TNF IL10 IFNG
48 11.42 TNF IL10RA IL10 CSF2 CCR5 CCR2
49 11.39 TNF IL10RA IL10
50 11.28 IFNG HLA-DRB1 CD4

GO Terms for Cytomegalovirus Retinitis

Cellular components related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.21 TNF IL10RA HLA-DRB1 HLA-DQB1 HLA-B HLA-A
2 integral component of plasma membrane GO:0005887 10.01 TNF HLA-B HLA-A CD9 CD8A CD4
3 extracellular space GO:0005615 9.97 TNF IL10 IFNL4 IFNG HLA-B CXCL12
4 cell surface GO:0009986 9.8 TNF HLA-DRB1 HLA-B HLA-A CD9 CD4
5 endocytic vesicle membrane GO:0030666 9.63 HLA-DRB1 HLA-DQB1 CD9
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DRB1 HLA-DQB1 CD9
7 MHC class I protein complex GO:0042612 9.48 HLA-B HLA-A
8 ER to Golgi transport vesicle membrane GO:0012507 9.46 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
9 external side of plasma membrane GO:0009897 9.28 TNF HLA-DRB1 HLA-B CXCL12 CD9 CD8A
10 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Biological processes related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.99 HLA-DRB1 HLA-DQB1 HLA-B HLA-A CD8A CD4
2 cell surface receptor signaling pathway GO:0007166 9.93 IFNG CD8A CD4 CCR5
3 cellular response to lipopolysaccharide GO:0071222 9.86 TNF IL10 CSF2 CCR5
4 cell chemotaxis GO:0060326 9.84 CXCL12 CCR5 CCR2
5 chemokine-mediated signaling pathway GO:0070098 9.8 CXCL12 CCR5 CCR2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IFNG CSF2
7 viral process GO:0016032 9.8 HLA-DRB1 HLA-B CXCL12 CD4 CCR5 CCR2
8 regulation of insulin secretion GO:0050796 9.79 TNF IFNG CARTPT
9 humoral immune response GO:0006959 9.74 TNF IFNG CCR2
10 cytokine-mediated signaling pathway GO:0019221 9.7 TNF IL10RA IL10 CSF2 CD4 CCR5
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.67 HLA-DRB1 HLA-DQB1
12 positive regulation of podosome assembly GO:0071803 9.66 TNF CSF2
13 positive regulation of chemokine biosynthetic process GO:0045080 9.65 TNF IFNG
14 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNG
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL10 IFNG
16 interferon-gamma-mediated signaling pathway GO:0060333 9.65 IFNG HLA-DRB1 HLA-DQB1 HLA-B HLA-A
17 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.64 CSF2 CD4
18 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.64 HLA-B HLA-A
19 positive regulation of JAK-STAT cascade GO:0046427 9.63 TNF IL10RA IL10
20 endothelial cell apoptotic process GO:0072577 9.62 TNF IL10
21 positive regulation of NMDA glutamate receptor activity GO:1904783 9.61 IFNG CCR2
22 regulation of synapse organization GO:0050807 9.61 TNF IL10RA IL10
23 fusion of virus membrane with host plasma membrane GO:0019064 9.6 CD4 CCR5
24 protection from natural killer cell mediated cytotoxicity GO:0042270 9.59 HLA-B HLA-A
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
26 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.58 HLA-DRB1 HLA-DQB1
27 positive regulation of interleukin-23 production GO:0032747 9.55 IFNG CSF2
28 entry into host cell GO:0030260 9.54 CD4 CCR5
29 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.52 HLA-DRB1 HLA-DQB1
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 TNF IFNG
31 receptor biosynthetic process GO:0032800 9.48 TNF IL10
32 immune response GO:0006955 9.44 TNF IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-B
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 TNF IFNG
34 positive regulation of nitrogen compound metabolic process GO:0051173 9.37 TNF IFNG
35 antigen processing and presentation GO:0019882 9.35 HLA-DRB1 HLA-DQB1 HLA-B HLA-A CD8A

Molecular functions related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.43 HLA-DRB1 CD4 CCR5
2 coreceptor activity GO:0015026 9.33 CD8A CD4 CCR5
3 MHC class II receptor activity GO:0032395 9.32 HLA-DRB1 HLA-DQB1
4 peptide antigen binding GO:0042605 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
5 cytokine activity GO:0005125 9.1 TNF IL10 IFNL4 IFNG CXCL12 CSF2

Sources for Cytomegalovirus Retinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....